Table 6.
DOE studies investigating other cell expansion.
| Cells | Experimental Design | Number of Factors | Factors | Year | Ref. |
|---|---|---|---|---|---|
| Human pancreatic duct cell | Full factorial 25 | 5 | bFGF, EGF, HGF, KGF, VEGF | 2012 | [100] |
| Vero | 210−6 Resolution III | 10 | (20 amino acids, Vitamin B1, Magnesium sulfate, Sodium phosphate), (Vitamins H, B2, and B9, Thymidine, Uracil, Xanthine, Hypoxanthine), (Vitamins B12, B3, and B7, Choline chloride, Pyridoxal), (Vitamins B3, B6, and BX, Putrescin), (Vitamins A, D2, and K3, Linoleic acids, Lipoic acids), (Deoxyribose, Adenine, Adenosine, Ethanolamine), (Plant and yeast extracts, EGF, Insulin), (Sodium citrate, Ferric chloride), (Glucose, Pyruvate), (Other) | 2010 | [106] |
| Murine hybridoma | 29−4 Resolution IV | 9 | Serum, Dissolved oxygen, Temperature, pH, Glucose, Glutamine, Lactate, Ammonium, Base medium concentration | 1993 | [108] |
| Murine myeloma | 25−1 Resolution V | 5 | pH, Temperature, Dissolved oxygen, Early/late feed regime, Seeding density | 2000 | [109] |
| Murine hybridoma | L8 | 4 | Stirring speed, Fetal bovine or calf serum, Serum concentration, Glucose and glutamine supplement | 2002 | [110] |
| Vero | L8 | 4 | Cytodex 1, Regulation of glucose, Initial glucose, Gln | 2006 | [107] |
| Caco-2 and HT29-MTX cells | L18 | 4 | MEM or DMEM medium, Seeding time, Seeding density, and Caco-2/HT29-MTX ratio | 2010 | [101] |
| Human umbilical vein endothelial cell (HUVEC) | Full factorial 24 | 4 | RGDS, IKVAV, YIGSR, Q11 1 | 2011 | [102] |
| RSM | 3 | RGDS, IKVAV, YIGSR 1 | |||
| Human peripheral blood mononuclear cell | 24−1 Resolution IV | 4 | Phosphatidyl choline, Polyamine supplement, Antioxidant supplement, Cholesterol | 2010 | [103] |
| RSM | 2 | Polyamine supplement, Cholesterol | |||
| Human prostate cancer cells | Plackett–Burman | 16 | Transferrin, Sodium selenite, Sodium L-ascorbate, Ferric citrate, L-glutathione, BSA, EGF, bFGF, Ethanolamine, Linoleic acid, Arachidonate, Thioglycerol, Hydrocortisone, Yeast hydrolysate, Penicillin-Streptomycin Solution, Succinic Acid | 2017 | [104] |
| RSM | 3 | EGF, FGF, Linoleic acid | |||
| Immortalized human erythroblast | 29−4 Resolution IV | 9 | BSA, EPO, Holo-transferrin, Hydrocortisone, Insulin, Fatty acid supplement, Lipid mixture solution, Non-essential amino acids supplement, SCF | 2018 | [105] |
| RSM | 3 | BSA, EPO, Fatty acid supplement |
Abbreviations: bFGF, basic fibroblast growth factor 2; EGF, epidermal growth factor; HGF, hepatocyte growth factor; KGF, keratinocyte growth factor; VEGF, vascular endothelial growth factor; MEM, Minimum Essential Medium with Earle’s Salts; DMEM, Dulbecco’s Modified Eagle’s Medium; EPO, erythropoietin; SCF, stem cell factor.1 RGDS, IKVAV, and YIGSR are peptides containing the indicated amino acid residues. Q11 is the structural peptide used as control matrix.